{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:01:26Z","timestamp":1789441286683,"version":"build-2803163510"},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate damage features and impact on survival by Vasculitis Damage Index (VDI) in a cohort of Turkish patients with Wegener\u2019s granulomatosis (WG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We enrolled 50 (25 female) patients with WG according to ACR criteria. Birmingham Vasculitis Activity Score (BVAS) and VDI were used to analyze disease activity and damage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Patients had kidney (82%), upper airway (72%), lung (70%), and nervous system (15%) involvement. Median age at diagnosis was 45 years, time to diagnosis was 3.5 months, and total followup time was 35.5 months. All but one patient was positive for antineutrophil cytoplasmic antibodies (ANCA). Mean final dose and duration of corticosteroid and cyclophosphamide was 15 \u00b1 14 g, 39 \u00b1 33 months and 36 \u00b1 34 g, 21 \u00b1 2 months, respectively. Mean early (e) BVAS were 20.2 \u00b1 7.1 (4\u201338) (median 21). Mean e-BVAS and e-VDI scores at presentation and final (f)-VDI scores at last visit were 20.2 \u00b1 7.1 (4\u201338), 3.1 \u00b1 1.7 (median 3) (0\u20137) and 4.4 \u00b1 2.6 (0\u201312), consecutively. Disease related damage was prominent in kidneys (50%) and upper airways (27%). Amenorrhea (90%), cataract (28%), and diabetes (24%) were the most frequent treatment related damages. Rapidly progressive glomerulonephritis at presentation (42%) progressed to endstage renal failure in 20%. Relapses occurred in 25% with mean BVAS of 6.5 \u00b1 2.3 (4\u201311). Survival rate was 77% at 37 months. Deaths occurred early (90% in the first year). f-VDI was high in patients who relapsed (6 \u00b1 3 vs 3.8 \u00b1 2.1, p = 0.03). Logistic regression analysis demonstrated that age at time of diagnosis and e-VDI were lower in survivors with OR = 0.9 (p = 0.06, 95% CI: 0.78\u20131) and OR = 0.5 (p = 0.04, 95%CI: 0.25\u20130.98), respectively. In this cohort, e-VDI score of 5 or more was related to death with 98% sensitivity and 56% specificity (p = 0.004) (CI: 0.66\u20130.95).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Disease related damage outweighed treatment related damage in our cohort of predominantly generalized disease activity. Early damage and older age were found to be predictors of final damage and death.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090387","type":"journal-article","created":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T03:59:30Z","timestamp":1260935970000},"page":"374-378","source":"Crossref","is-referenced-by-count":32,"title":["Predictors of Damage and Survival in Patients with Wegener\u2019s Granulomatosis: Analysis of 50 Patients"],"prefix":"10.3899","volume":"37","author":[{"given":"SEVIL","family":"KAMALI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BURAK","family":"ERER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BAHAR","family":"ARTIM-ESEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AHMET","family":"GUL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LALE","family":"OCAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MERAL","family":"KONICE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ORHAN","family":"ARAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MURAT","family":"INANC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"2018112909215961000_37.2.374.1","unstructured":"Stone JH Hoffman GS . Wegener\u2019s granulomatosis. In: Hochberg MC Silman AJ Smolen JS Weinblatt ME Weisman MH editors. Rheumatology. Philadelphia: Elsevier Limited; 2008 1533\u201344."},{"key":"2018112909215961000_37.2.374.2","first-page":"1357","article-title":"The future of damage assessment in vasculitis","volume":"34","author":"Seo","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909215961000_37.2.374.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400222"},{"key":"2018112909215961000_37.2.374.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.5.572"},{"key":"2018112909215961000_37.2.374.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0499-0"},{"key":"2018112909215961000_37.2.374.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21117"},{"key":"2018112909215961000_37.2.374.7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2018112909215961000_37.2.374.8","unstructured":"http:\/\/www.vasculitis.org\/scoring\/BVAS%202003.pdf."},{"key":"2018112909215961000_37.2.374.9","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/90.6.391"},{"key":"2018112909215961000_37.2.374.10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2249.1995.tb06161.x","article-title":"European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials.","volume":"101","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2018112909215961000_37.2.374.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-1-76"},{"key":"2018112909215961000_37.2.374.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020286"},{"issue":"116","key":"2018112909215961000_37.2.374.13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"15","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2018112909215961000_37.2.374.14","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92205-V"},{"key":"2018112909215961000_37.2.374.15","first-page":"127","volume":"88","author":"Jayne","year":"1995","journal-title":"ANCA and predicting relapse in systemic vasculitis QJM"},{"key":"2018112909215961000_37.2.374.16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","article-title":"Relapse rate, renal survival and cancer morbidity in patients with Wegener\u2019s granulomatosis or microscopic polyangiitis with renal involvement","volume":"9","author":"Westman","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2018112909215961000_37.2.374.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2006.11.025"},{"key":"2018112909215961000_37.2.374.18","first-page":"1237","article-title":"Longterm outcome of Wegener\u2019s granulomatosis in patients with renal disease requiring dialysis","volume":"27","author":"Mekhail","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909215961000_37.2.374.19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-113-9-656","article-title":"Clinical course of anti-neutrophil cytoplasmic autoantibodies-associated glomerulonephritis and systemic vasculitis","volume":"113","author":"Falk","year":"1990","journal-title":"Ann Intern Med"},{"key":"2018112909215961000_37.2.374.20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1681\/ASN.V7123","article-title":"Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Hogan","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2018112909215961000_37.2.374.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.6.585"},{"key":"2018112909215961000_37.2.374.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00003"},{"key":"2018112909215961000_37.2.374.23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J"},{"key":"2018112909215961000_37.2.374.24","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909215961000_37.2.374.25","first-page":"427","article-title":"et al. Wegener\u2019s granuloma: A series of 265 British cases seen between 1975 and 1985. A report by a subcommittee of British Thoracic Society Research Committee","volume":"83","author":"Anderson","year":"1992","journal-title":"QJM"},{"key":"2018112909215961000_37.2.374.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.10.1059"},{"key":"2018112909215961000_37.2.374.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)80066-0"},{"key":"2018112909215961000_37.2.374.28","doi-asserted-by":"crossref","unstructured":"Bligny D Mahr A Toumelin PL Mouthon L Guillevin L . Predicting mortality in systemic Wegener\u2019s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004;51:83\u201391.","DOI":"10.1002\/art.20082"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T04:15:18Z","timestamp":1634357718000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,15]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,2,9]]},"published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.3899\/jrheum.090387"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090387","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,15]]}}}